STOCK TITAN
  1. Home
  2. News
  3. CYBN

Cybin Inc. - CYBN STOCK NEWS

Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.

Cybin Inc. (symbol: CYBN) is a pioneering biopharmaceutical company dedicated to addressing mental health challenges through innovative therapeutics. Specializing in psychedelic-based therapies, Cybin focuses on developing novel compounds, delivery mechanisms, and protocols aimed at treating a range of psychiatric and neurological conditions.

Cybin's core business revolves around advancing clinical-stage programs designed to harness the potential of psychedelics. The company is engaged in creating safe and effective treatments for conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD). Their research and development efforts highlight the transformative potential of these therapies in modern medicine.

Recently, Cybin has achieved significant milestones, including progress in their proprietary drug delivery technologies. These advancements aim to improve the administration and efficacy of psychedelic compounds, ensuring patients receive the maximum therapeutic benefit. Their innovative approach extends to developing new chemical entities (NCEs) that hold promise in the field of mental health treatment.

Financially, Cybin remains robust and committed to its growth strategy. The company has secured strategic partnerships and collaborations that bolster its research initiatives and clinical trials. These alliances are crucial in accelerating the development and commercialization of their therapeutic solutions.

Cybin's product pipeline is impressive, featuring multiple candidates in various stages of development. These include CYB001, a formulation targeting major depressive disorder, and CYB003, designed for anxiety disorders. Each product undergoes rigorous testing to ensure safety and effectiveness.

In summary, Cybin Inc. is at the forefront of revolutionizing mental health treatment through psychedelic-based therapies. Their dedication to advancing science and addressing unmet medical needs positions them as a significant player in the biopharmaceutical industry.

News

Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City

Rhea-AI Summary
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) announced an R&D investor briefing featuring a key opinion leader panel discussing topline Phase 2 safety and efficacy data for CYB003, a deuterated psilocybin analog for treating major depressive disorder. The event will include a panel discussion with key opinion leaders on data and study designs, the current treatment landscape in depression, and the future role of psychedelics. Key opinion leaders include Dr. Maurizio Fava, M.D., Massachusetts General Hospital and Harvard Medical School, and Dr. Gitte Moos Knudsen, Professor, Chief Neurologist, DMSc, Neurobiology Research Unit, Rigshospitalet and University of Copenhagen, Denmark.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
conferences
-
News

Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023

Rhea-AI Summary
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) will host an R&D briefing to share topline Phase 2 safety and efficacy data for CYB003, its deuterated psilocybin analog for major depressive disorder treatment. The event, on November 30, 2023, will feature an overview of the recently completed Phase 1/2 trial and a detailed review of the safety and efficacy data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
clinical trial
-
News

Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting

Rhea-AI Summary
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) announced a poster presentation at Neuroscience 2023 hosted by the Society for Neuroscience. The poster focuses on the discovery and preclinical characterization of 2,5-dimethoxy-4-thiofluoroalkyl phenethylamines as potent and long-acting serotonin 5-HT2 receptor agonists, with the potential to treat neuropsychiatric or neurological disorders. Geoff Varty, Ph.D., Head of Research & Development at Cybin, highlighted the company's commitment to revolutionizing mental healthcare through innovative psychedelic-based treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
none
News

Cybin Reports Second Quarter Financial Results and Recent Business Highlights

Rhea-AI Summary
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) reported positive Phase 2 interim data for CYB003, its deuterated psilocybin analog, in major depressive disorder. The company also closed a unit offering of up to US$64 (C$88.4) million, strengthened its patent portfolio, and completed the acquisition of Small Pharma Inc. Key upcoming milestones include the topline clinical readout of Phase 2 efficacy data for CYB003 and CYB004 and SPL028 in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
earnings
-
News

Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional Shareholders

Rhea-AI Summary
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) has successfully completed its underwritten offering, raising US$30 million through the issuance of 66,666,667 units at a price of US$0.45 per unit. The company plans to use the net proceeds for the progression of its CYB003 and deuterated DMT programs, as well as for general corporate and working capital purposes. Cybin expects pivotal clinical data readouts from its Phase 1/2a trial of CYB003 and its Phase 1 trial of CYB004 and SPL028 in Q4 of 2023 and 2024. The capital raised is anticipated to provide Cybin with over US$100 million in access, supporting the completion of value-driving clinical milestones and enabling the focus on clinical execution to bring improved therapeutic options to patients in need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
none
-
News

Cybin Announces up to US$64 Million Offering of Units

Rhea-AI Summary
Cybin Inc. (CYBN) Announces US$30 Million Firm Commitment Underwritten Offering to Revolutionize Mental Healthcare with Next-Generation Psychedelic Treatment Options
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.25%
Tags
none
News

Cybin to Participate at the 2023 Milken Institute Future of Health Summit

Rhea-AI Summary
CEO Doug Drysdale to speak on panel
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
conferences
-
News

Breakthrough Results: Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose - Comprehensive Topline Data Anticipated by Q4 2023

Rhea-AI Summary
Cybin Inc. announces Phase 2 interim results for CYB003, its proprietary deuterated psilocybin analog, showing a rapid and significant reduction in symptoms of depression three weeks after a single 12mg dose compared to placebo. The reduction in major depressive disorder symptoms was superior in participants assigned to CYB003 by 14.08 points (p=0.0005). Favorable safety and tolerability profile. Conference call scheduled for November 1, 2023, to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.75%
Tags
earnings
-
News

Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline

Rhea-AI Summary
Cybin Inc. provides an update on its clinical-stage programs and upcoming milestones. They recently released positive Phase 2 interim data for CYB003 in major depressive disorder (MDD), showing significant improvement in depression symptoms. The complete Phase 2 topline data for CYB003 in MDD and Phase 1 data readouts for CYB004 and SPL028 are expected in the coming months. Cybin plans to run four clinical studies in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.75%
Tags
none
News

Cybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose - Full Topline Data on Track for Q4 2023

Rhea-AI Summary
Cybin Inc. announces Phase 2 interim results for CYB003, its deuterated psilocybin analog, showing rapid and significant reduction of depression symptoms three weeks after a single 12mg dose compared to placebo. The mean MADRS score reduction was -14 points, with a response rate of 53.3% and a remission rate of 20%. The drug demonstrated favorable safety and tolerability. Full topline data is expected by Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.77%
Tags
earnings clinical trial

FAQ

What is the current stock price of Cybin (CYBN)?

The current stock price of Cybin (CYBN) is $10.15 as of November 5, 2024.

What is the market cap of Cybin (CYBN)?

The market cap of Cybin (CYBN) is approximately 202.3M.

What is Cybin Inc.?

Cybin Inc. is a biopharmaceutical company focused on developing psychedelic-based therapies for treating mental health conditions.

What does Cybin Inc. specialize in?

Cybin specializes in creating safe and effective treatments using psychedelic compounds to address psychiatric and neurological conditions.

What are the core areas of Cybin's research?

Cybin's research focuses on advancing psychedelic-based therapies, developing novel compounds, and improving drug delivery mechanisms.

What recent achievements has Cybin Inc. made?

Cybin has made significant progress in drug delivery technologies and the development of new chemical entities for mental health treatment.

Can you name some of Cybin's product candidates?

Cybin's pipeline includes CYB001 for major depressive disorder and CYB003 for anxiety disorders, among other candidates.

How does Cybin contribute to mental health treatment?

Cybin contributes by developing innovative psychedelic-based therapies aimed at providing effective treatments for various mental health conditions.

Has Cybin formed any strategic partnerships?

Yes, Cybin has established strategic partnerships and collaborations to support its research and clinical trials.

What is the significance of Cybin's drug delivery technologies?

Cybin's drug delivery technologies enhance the administration and therapeutic efficacy of psychedelic compounds.

What conditions are Cybin's therapies aimed at treating?

Cybin's therapies target psychiatric and neurological conditions such as depression, anxiety, and PTSD.

Where can I find the latest news about Cybin Inc.?

The latest news and updates about Cybin Inc. can be found on their official website and financial news platforms like StockTitan.

Stock CYBN logo
Cybin Inc.

NYSE:CYBN

CYBN Rankings

#3851 Ranked by Market Cap
N/A Ranked by Dividends

CYBN Stock Data

202.33M
19.99M
6.35%
38.41%
3.28%
Biotechnology
Healthcare
Link
United States of America
Toronto